Case study – Alcon – Novartis Spin-Off: Alcon to become standalone Trading Company
Posted on04 Jul 2018
Comments0
Novartis AG intends to spinoff its ophthalmology division, Alcon, into a separately-traded standalone company. Preset: Novartis acquired Alcon in 2011. The Alcon... Read More
Alcon Cares Project 100 commits to reducing cataract blindness globally
Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce... Read More
USFDA grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%
— Developed with efficacy data at 24 hours, post dose, to provide one-drop daily ocular itch relief associated with allergic conjunctivitis (eye... Read More